Prescient Therapeutics Ltd (ASX:PTX) CEO and managing director Steven Yatomi-Clarke chats with Andrew Scott from Proactive about the company’s strategic collaboration agreement with the University of Texas MD Anderson Cancer Center, which is the worlds biggest cancer centre. They have joined forces to create adaptable CAR-T cell therapies to treat blood cancers. Yatomi-Clarke discusses the kick-off meeting that is due to take place this week.
Prescient Therapeutics hails collaboration with MD Anderson Cancer Center for blood cancer therapy
